Skip to main content

Table 1 Description of the sample and the prevalence of the diagnostic time of up to 3 and 12 months of symptons according to the independente variables in patients with rheumatoid arthritis of Blumenau, Santa Catarina, Brazil, 2014

From: Prevalence and factors associated with diagnosis of early rheumatoid arthritis in the south of Brazil

Variables

Sample

Diagnostic up to 3 months

Diagnostic up to 12 months

N

%

Prevalence(%)

CI 95%

p

Prevalence(%)

CI 95%

p

Total

296

100,0

27,7%

(22,5–32,8)

 

64,8%

(59,3-70,3)

 

Sex (n = 296)

0,098a

  

0,708a

 Male

48

16,2

37,5

(23,2-51,7)

 

62,5

(48,2-76,7)

 

 Female

248

83,8

25,8

(20,3–31,2)

 

65,3

(59,3-71,2)

 

Age in years (n = 287)

0,227b

  

0,893b

 20–39

16

5,6

12,5

(5, 7–30,7)

 

62,5

(35,8-89,1)

 

 40–59

146

50,9

26,7

(19,4–33,9)

 

65,7

(57,9-73,5)

 

  ≥ 60

125

43,5

29,6

(21,5–37,7)

 

64,1

(55,4-72,5)

 

Education in completed years (n = 284)

0,447b

  

0,093b

 0–4

106

37,3

27,4

(18,6–36,2)

 

70,5

(61,5-79,5)

 

 5–8

76

26,7

21,1

(11,6–30,4)

 

64,4

(53,4-75,4)

 

  > 9

102

35,9

32,1

(23,1- 41,1)

 

59,4

(49,9-68,9)

 

Current monthly personal income in minimum wages (n = 248)

0,799b

  

0,493b

 Third tertile (higher)

82

33,1

28,5

(18,7–38,4)

 

59,5

(48,8-70,2)

 

 Second tertile

82

33,1

25,6

(15,9–35,2)

 

65,8

(55,3-76,3)

 

 First tertile (lower)

84

33,8

26,8

(17,1–36,6)

 

64,6

(54,1-75,2)

 

Body mass index (Kg/m2) (n = 285)

0,012b

  

0,001b

  ≤ 24,9

110

38,6

36,3

(27,2-45,4)

 

75,4

(67,2-83,6)

 

 25–29,9

113

39,7

24,7

(16,7–32,8)

 

61,9

(52,8-71,1)

 

  ≥ 30

62

21,7

19,3

(9,2–29,3)

 

51,6

(38,8-64,4)

 

Type of service in the last 12 months (n = 269)

0,166b

  

0,515b

 Public healthcare system

113

42,1

23,8

(15,9–31,8)

 

64,6

(55,7-73,4)

 

 Supplementary healthcare system

84

31,2

27,3

(17,7–37,1)

 

65,4

(55,2-75,7)

 

 Fee-for-service care

72

26,7

33,3

(22,3-44,3)

 

69,9

(58,6-80,2)

 

Total number of consultations with a rheumatologist in the last 12 months (n = 281)

0,165b

  

0,069b

 0–1

42

15,0

33,3

(18,4-48,2)

 

69,1

(54,4-83,6)

 

 2–3

126

44,9

23,0

(15,5 –30,4)

 

58,7

(50,0-67,4)

 

  ≥ 4

113

40,1

30,9

(22,3–39,6)

 

69,9

(61,3-78,4)

 

Disease time in months (n = 235)

0,193a

  

0,102a

 0–24

37

15,7

37,8

(21,4-54,2)

 

75,6

(61,1-90,1)

 

  > 24

198

84,3

27,2

(21,1–33,5)

 

61,6

(54,7-68,4)

 

Use of cs DMARD (n = 296)

0,396a

  

0,994a

 Yes

202

68,2

29,2

(22,8–35,5)

 

64,8

(58,2-71,4)

 

 No

94

31,7

24,4

(15,6–33,3)

 

64,8

(55,1-74,7)

 

Use of TNFi (ADA + ETA+IFX) (n = 288)

0,960a

  

0,592a

 Yes

75

26,1

28,0

(17,5–38,4)

 

61,3

(50,1-72,6)

 

 No

213

73,9

27,6

(21,6–33,7)

 

64,7

(58,3-71,2)

 

HAQ (n = 165)

0,904b

  

0,211b

 0–1 (mild)

65

39,4

24,6

(13,8–35,3)

 

55,3

(42,9-67,7)

 

 1,1–2 (moderate)

59

35,7

32,2

(19,9-44,4)

 

69,4

(57,3-81,5)

 

 2,1–3 (severe)

41

24,9

24,3

(10,6–38,1)

 

65,8

(50,7-81,0)

 

Presence of radiological changes (erosions) in hands (n = 237)

0,814a

  

0,665a

 No

89

37,5

26,9

(17,5–36,3)

 

66,2

(56,2-76,3)

 

 Yes

148

62,5

28,3

(21,1–35,7)

 

63,5

(55,6-71,3)

 

Current professional situation (237)

0,325b

  

0,132b

 Working

77

32,5

23,3

(13,7 – 33,1)

 

59,7

(48,5 – 70,9)

 

 Health insurance

29

12,2

24,1

(7,5 – 40,7)

 

55,1

(35,9 – 74,4)

 

 Disability retirement

65

27,5

27,6

(16,5 – 38,8)

 

60,1

(47,7 – 77,2)

 

 Retirement for time of service

66

27,8

30,3

(18,9 – 41,6)

 

72,2

(61,9 – 83,7)

 
  1. csDMARD conventional synthetic disease-modifying antirheumatic drugs, TNFi tumor necrosis factor inhibitors ADA adalimumab, ETA etanercept, IFX infliximab, HAQ health assessment questionnaire; CI 95%: confidence interval of 95%
  2. aChi-square test bWald’s linear trend test